Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Alliance Pharma plc    APH   GB0031030819

ALLIANCE PHARMA PLC (APH)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Alliance Pharma : first-half revenue rises on strong sales abroad

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2017 | 09:13am CEST

(Reuters) - British speciality pharmaceutical company Alliance Pharma Plc (>> Alliance Pharma plc) on Wednesday reported an 8.4 percent rise in first-half revenue, helped by international sales of its scar reduction product and eye supplement.

(Reuters) - British speciality pharmaceutical company Alliance Pharma Plc (>> Alliance Pharma plc) on Wednesday reported an 8.4 percent rise in first-half revenue, helped by international sales of its scar reduction product and eye supplement.

The company, listed on London's junior stock market, said revenue rose to 50.3 million pounds for the six months ended June 30, from 46.4 million pounds a year ago.

Underlying profit before tax rose 1.7 percent to 11.9 million pounds during the period.

Sales of the company's top-selling scar-diminishing product, Kelo-cote, rose to 6.2 million pounds in the first half from 4.1 million pounds a year ago.

MacuShield, the company's nutritional supplement to treat age-related vision loss, posted a 67 percent rise in first-half sales at 3.4 million pounds.

Alliance Pharma, which bought the healthcare assets of Sinclair Pharma (>> Sinclair Pharma PLC) for 128 million pounds in December 2015, now owns about 90 pharmaceutical and healthcare products.

"With the integration of the Sinclair Pharma products now complete we are strategically positioned for growth and, with leverage levels reducing, we are now able to pursue bolt-on acquisitions," Chairman Andrew Smith said.

Alliance Pharma said it believed there were grounds to re-open discussions with the UK's medicinal product regulator on Diclectin, a drug for nausea during pregnancy, which failed to receive approval earlier this year.

However, analysts have said the regulatory decision meant the company was also looking for a replacement for Diclectin.

The replacement is likely to come via acquisition or by obtaining licenses from other companies rather from within the current portfolio, analysts have said.

(Reporting By Justin George Varghese in Bengaluru; Editing by Amrutha Gayathri)

Stocks treated in this article : Alliance Pharma plc, Sinclair Pharma PLC
Stocks mentioned in the article
ChangeLast1st jan.
SINCLAIR PHARMA PLC -1.46% 18.6 Delayed Quote.-27.75%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLIANCE PHARMA PLC
06/19ALLIANCE PHARMA : Result of Placing
PU
06/19ALLIANCE PHARMA : Nizoral Acquisition in APAC and Proposed Placing
PU
06/14ALLIANCE PHARMA PLC : Ex-dividend day for final dividend
FA
06/07ALLIANCE PHARMA : Positive Opinion on Diclectin
PU
05/16ALLIANCE PHARMA : Notification of Major Holdings
PU
05/10VENTURE LIFE : Lypsyl owner Alliance extends its contract with Venture Life
AQ
04/19ALLIANCE PHARMA : Annual Report and AGM Notice
PU
04/19ALLIANCE PHARMA : Notification of Major Holdings
PU
04/17ALLIANCE PHARMA : Disposal of Chinese rights to Forceval
PU
04/13ALLIANCE PHARMA : to present at the UK Investor Show
PU
More news
Financials ( GBP)
Sales 2018 118 M
EBIT 2018 30,6 M
Net income 2018 22,0 M
Debt 2018 56,4 M
Yield 2018 1,49%
P/E ratio 2018 20,83
P/E ratio 2019 19,16
EV / Sales 2018 4,45x
EV / Sales 2019 4,05x
Capitalization 466 M
Chart ALLIANCE PHARMA PLC
Duration : Period :
Alliance Pharma plc Technical Analysis Chart | APH | GB0031030819 | 4-Traders
Technical analysis trends ALLIANCE PHARMA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 0,85  GBP
Spread / Average Target -12%
EPS Revisions
Managers
NameTitle
Peter Jonathan Butterfield Chief Executive Officer & Executive Director
David John Cook Chairman
Stephen Kidner Chief Scientific & Operations Officer
Andrew Timothy Franklin Chief Financial Officer & Director
John Dawson Non-Executive Director & Head-Investor Relations
Sector and Competitors